Integrative Oncology Outcome Studies

Abstract

Integrative oncology - the structured use of complementary interventions alongside conventional cancer treatment - has moved from fringe to mainstream in the last two decades, with dedicated clinics now standard in most large cancer centres in the United States and a growing European footprint. The outcome literature has grown in step, but remains fragmented: different intervention classes are reported against different endpoints, making cross-class comparison unusually difficult. We pulled together 104 clinical outcome studies published between 2010 and 2024 in adult oncology populations, and sorted them into five intervention frames: I1 (Ayurvedic adjunctive protocols), I2 (mind-body interventions - yoga, meditation, pranayama), I3 (nutritional and dietary integration), I4 (herbal safety and drug-interaction monitoring), and I5 (integrative symptom management). Each frame was scored on the Integrative Oncology Validation Index (IOVI), a weighted composite across clinical effect size, safety profile, quality-of-life endpoints, reproducibility, and integration feasibility. Mind-body interventions (I2) and integrative symptom management (I5) scored highest, at IOVI 0.892 and 0.864, both with strong QoL evidence and good safety records. Ayurvedic adjunctive protocols (I1) showed encouraging but less consistent results, mostly due to heterogeneous protocol specification. Our reading is that integrative oncology now carries a defensible evidence base for QoL and symptom endpoints, with disease-modifying claims remaining the domain where caution is still warranted.